MedTrace Logo

Polypectomy in Patients Taking Dual Antiplatelet Agents

NCT02865824 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-08-17

No results posted yet for this study

Summary

Current guidelines recommend discontinuation of antiplatelets (i.e clopidogrel) for 7 days in patients taking DAT (dual antiplatelet therapy) before colonoscopy and polypectomy. The purpose of this study was to examine if a) discontinuation of these drugs reduces bleeding risks during polypectomy and if b) discontinuation of these drugs increases the occurence of thromboembolic events.

Conditions

  • Colonic Polyps

Interventions

DRUG

Continue thienopyridine

Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy

DRUG

Discontinue thienopyridine

Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy

Sponsors & Collaborators

  • Incheon St.Mary's Hospital

    lead OTHER

Principal Investigators

  • Joon Sung Kim, MD · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865824 on ClinicalTrials.gov